Kristin Abate - 01 Sep 2026 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Reporting relationship: Chief Accounting Officer
Issuer ticker: KPTI
Reported as of: 01 Sep 2026
Net transaction value: -$38.38
SEC form: 4
Accepted by SEC: 02 Sep 2026, 16:57:47 UTC
Prior SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate

Key filing fact

Kristin Abate filed Form 4 for Karyopharm Therapeutics Inc. (KPTI) on 02 Sep 2026.

Key facts

This page summarizes Kristin Abate's Form 4 filing for Karyopharm Therapeutics Inc. (KPTI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 02 Sep 2026, 16:57.

Change

Previous filing in this sequence was filed on 15 May 2026.
Current net transaction value: -$38.38.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002045943 Primary reporting owner

Abate Kristin

Relationship: Chief Accounting Officer
Address: C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, NEWTON
Signature: /s/ Nancy Smith as Attorney-in-Fact for Kristin Abate
Signature date: 02 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KPTI transaction

Common Stock

Sale

Transaction value: $38.38
Shares: -19
Change %: -0.08%
Price: $2.02
Shares after: 23,782
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.